Latest news with #ITM
Associated Press
6 days ago
- Business
- Associated Press
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope. 'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.' The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production. Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. About the ILL, Institut Laue-Langevin The ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research communities. ITM Contact Corporate Communications Kathleen Noonan / Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected] ILL Contact Radionuclide Production Ulli Köster Phone: (+33) (0)4 76 20 71 54 Email: [email protected] Communications Catarina Espirito Santo Phone: (+33) (0)4 76 20 71 07 Email: [email protected] Attachment
Yahoo
6 days ago
- Business
- Yahoo
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope. 'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.' The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production. Dr. Ken Andersen, Director of the Institut Laue-Langevin added, 'ILL operates the world-leading neutron source for research by neutron scattering and in nuclear and particle physics. Moreover, ILL's reactor provides irradiation positions at exceptionally high neutron flux that are exploited both for fundamental research and the production of radionuclides for medical applications. ILL is proud of the longstanding collaboration with ITM, regularly performing irradiations of Ytterbium-176 targets for ITM over the last 15 years, and looks forward to an even closer partnership in the coming years.'About Radiopharmaceutical Therapy (RPT)Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. the ILL, Institut Laue-LangevinThe ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research ContactCorporate CommunicationsKathleen Noonan / Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ ContactRadionuclide ProductionUlli Köster Phone: (+33) (0)4 76 20 71 54Email: koester@ Espirito SantoPhone: (+33) (0)4 76 20 71 07Email: communication@ Attachment 20250616_ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Hans India
6 days ago
- Business
- Hans India
Higher Implied Volatility points to wider price swings
The support level fell by 1,200 points to 22,800PE, while the resistance level remained at 26,000CE for a second consecutive week. The 26,000CE has highest Call OI followed by 25,000/ 25,500/ 25,700/ 25,200/ 25,300/ 25,100/ 25,900 strikes, while 25,000/ 24,800/ 25,700/ 25,800 strikes recorded reasonable to heavy build-up of Call OI. Few OTM strikes in the 25,950-26,150 range witnessed moderate Call OI fall. Implied Volatility (IV) of 22,800PE, which holds the highest Put OI base, rose to 29.72, while the IV was marginally up at 26,000CE, which has a maximum Call OI base. Coming to the Put side, maximum Put OI is seen at 22,800PE followed by 23,500/ 24,000/ 23,000/ 22,850/ 23,800/ 24,300/ 24,100/ 24,400/ 24,500/ 24,600 strikes. Further, 22,800/ 23,000/ 23,500/ 23,800/ 24,000/ 24,500/ 24,600 strikes posted moderate to reasonable addition of Put OI. ITM strikes in the 24,800-25,700 range suffered minute Put OI decline. Dhirender Singh Bisht, associate vice-president (technical research-equity) at SMC Global Securities Ltd, said: 'From the derivatives front, marginal Open Interest addition was seen by option writers in absence of any clear direction. Maximum Open Interest in Calls was seen at 25,000 strike, while marginal Put writing was observed at 24,600 & 24,500 strikes.' 'Indian markets ended lower in the week gone by on the back of weak global cues. The knee jerk reaction was seen largely due to sharp rise in crude oil prices as geopolitical tensions rose in the Middle East. However, a moderation in CPI inflation helped limit the downside,' observed Bisht. For the week ended June 13, 2025, BSE Sensex closed at 81,118.60 points, a net fall of 1,070.39 points or 1.30 per cent, from the previous week's (June 6) closing of 82,188.99 points. NSE Nifty too moved down by 284.45 points or 1.13 per cent to 24,718.60 points from 25,003.05 points a week ago. Bisht forecasts: 'On the technical front, Nifty slipped below its short-term moving average (20DEMA) once again, but witnessed a swift rebound after testing the lower end of the recent consolidation range (24,500–25,200). This suggests a possibility of continued consolidation in the index. For the upcoming week, Nifty is likely to remain in range once again and witness a phase of consolidation within a broader range of 24500-25500. However a decisive breakout on any side beyond defined range could further fuel momentum into the index.' India VIX rose 7.60 per cent to 15.08 level. 'Implied Volatility (IV) for Nifty's Call options settled at 13.43 per cent, while Put options concluded at 14.10 per cent. The India VIX, a key market volatility indicator, closed the week at 14.02 per cent. Bank Nifty Bank Nifty NSE's banking index closed the week at 55,527.35 points, a fall of 1,051.05 or 1.85 per cent from the previous week's closing of 56,578.40 points.
Yahoo
13-06-2025
- Business
- Yahoo
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, 'Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging', on Sunday, June 22 in the Neuroendocrine - Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors. Symposium DetailsThe symposium, 'Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry,' will take place on Sunday June 22, from 6:30 pm – 7:30 pm CDT. The symposium will feature an overview of the GEP-NET treatment landscape, including findings from the Phase 3 COMPETE trial, and perspectives on dosimetry standardization today and in the future. COMPETE evaluated n.c.a 177Lu-edotreotide (also known as ITM-11) in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and ITM announced the positive Phase 3 results in March 2025. Date and Time: Sunday, June 22, from 6:30 pm – 7:30 pm CDTLocation: Ernest N. Morial Convention Center, New Orleans, LA; Room R04-R05Speakers and Topics: GEP-NET treatment landscape, COMPETE trial results, and COMPOSE trial designJonathan Strosberg, MD; Section Head, Neuroendocrine Division Program Chair, Gastrointestinal Department Oncology Research Program Moffitt Cancer Center COMPETE dosimetry sub-study and the evolution of dosimetryJohn Sunderland, PhD; Professor of Radiology Nuclear Medicine Division University of Iowa Dr. Celine Wilke Participates in Entrepreneur's PanelAs part of the SNMMI conference, Dr. Celine Wilke, ITM's Chief Medical Officer will participate in the 'Entrepreneur's Panel: Community Based Sites – Accelerating Clinical Trials and Expanding Access,' on Saturday, June 21, from 3:30 – 4:45 pm will further be present at the conference with a booth (booth number: 1001) providing information on the company's latest innovations in radiopharmaceutical therapy (RPT), its pipeline of RPT therapeutics and the company's capabilities to produce high-quality medical radioisotopes for global partners and its own pipeline. About the COMPETE TrialThe COMPETE trial evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Attachment 20250613_ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Yahoo
12-06-2025
- Business
- Yahoo
TopLine Financial Credit Union Opens New Maple Grove West Branch on June 9, 2025
TopLine is thrilled to announce the opening of their new Maple Grove West branch located at 7015 Alvarado Lane North, Maple Grove, Minnesota 55311 TopLine's New Maple Grove West Location MAPLE GROVE, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- TopLine Financial Credit Union, a Twin Cities-based member-owned financial services cooperative, recently opened a new full-service Maple Grove West branch on June 9, 2025, located at 7015 Alvarado Lane North, Maple Grove, MN 55311. The new Maple Grove West branch will provide personal service as well as self-service convenience with a new innovative 24/7 Interactive Teller Machine (ITM) that provides members with remote assistance service, combining the convenience of ATMs with the personalized experience of a branch visit. Financial product and service offerings include: savings and checking accounts, auto loans, home loans, personal loans, student loans, mortgage services, investment services, small business and commercial services, insurance agency, remote access, as well as financial education and counseling from TopLine Certified Credit Union Financial Counselors. "We are excited to announce the opening of our new Maple Grove West location, further expanding our presence in the surrounding communities of Maple Grove, Corcoran, Hamel and Media to offer accessible financial services to more consumers and small business owners," stated Mick Olson, President and CEO of TopLine Financial Credit Union. "Our new branch reflects our dedication to delivering tailored financial solutions that empower individuals and families to realize their dreams, whether it's buying a home, funding education, saving for retirement, protecting assets, or starting a small business. We look forward to creating lifelong connections and serving as a trusted financial partner for individuals and families across these vibrant communities.' TopLine will be holding a Grand Opening Celebration at the new location during the week of June 23 – 28, 2025. The community is invited to visit the branch in-person for exclusive specials, tasty treats, and a 'We'll Pay Your Phone Bill for a Month up to $150' raffle as a way to recognize the Bell System telephone workers who started the credit union 90 years ago. To learn more visit TopLine will be hosting a Ribbon Cutting Celebration in partnership with the Minneapolis Regional Chamber at the new location, 7015 Alvarado Lane North, Maple Grove, MN 55311, on Wednesday, July 9th from 2:00pm – 4:00pm. Everyone is welcome and refreshments will be served. TopLine Financial Credit Union, a Twin Cities-based credit union, is Minnesota's 9th largest credit union, with assets of over $1.1 billion and serves over 70,000 members. Established in 1935, the not-for-profit financial cooperative offers a complete line of financial services from its ten branch locations — in Bloomington, Brooklyn Park, Champlin, Circle Pines, Coon Rapids, Forest Lake, Maple Grove, Plymouth, St. Francis and in St. Paul's Como Park — as well as by phone and online at Membership is available to anyone who lives, works, worships, attends school or volunteers in Anoka, Benton, Carver, Chisago, Dakota, Hennepin, Isanti, Kanabec, Mille Lacs, Pine, Ramsey, Scott, Sherburne, Washington and Wright counties in Minnesota and their immediate family members, as well as employees and retirees of Anoka Hennepin School District #11, Anoka Technical College, Federal Premium Ammunition, Hoffman Enclosures, Inc., GRACO, Inc., and their subsidiaries. Visit us on our Facebook or Instagram. To learn more about the credit union's foundation, visit CONTACT:Vicki Roscoe EricksonSenior Vice President and Chief Marketing OfficerTopLine Financial Credit Unionverickson@ | 763.391.0872 A photo accompanying this announcement is available at
